SUMMARIZED QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Details) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended								12 Months Ended
	Sep. 03, 2024	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Effect of Fourth Quarter Events [Line Items]
Net sales		$ 1,385.8	$ 1,354.4	$ 1,369.4	$ 1,329.9	$ 1,266.4	$ 1,243.4	$ 1,278.9	$ 1,221.3	$ 5,439.5	$ 5,010.0	$ 4,464.0
Gross profit		1,093.6	1,091.5	1,093.9	1,043.0	1,015.4	992.8	1,031.1	992.3	4,322.0	4,031.6	3,740.3
Income from continuing operations, net of tax		345.0	362.1	364.0	324.9	333.1	334.9	251.4	300.6	1,396.0	1,220.0	1,324.0
Income from discontinued operations, net of tax		39.3	2,707.3	1.0	26.1	36.6	48.8	54.1	39.9	2,773.7	179.4	197.9
Net income		384.3	3,069.4	365.0	351.0	369.7	383.7	305.5	340.5	4,169.7	1,399.4	1,521.9
Net income attributable to Edwards Lifesciences Corporation.		$ 385.6	$ 3,070.8	$ 366.3	$ 351.9	$ 369.9	$ 384.9	$ 307.1	$ 340.5	$ 4,174.6	$ 1,402.4	$ 1,521.9
Basic
Continuing operations (in dollars per share)		$ 0.58	$ 0.61	$ 0.61	$ 0.54	$ 0.55	$ 0.55	$ 0.42	$ 0.49	$ 2.34	$ 2.02	$ 2.14
Discontinued operations (in dollars per share)		0.07	4.53	0	0.04	0.06	0.08	0.09	0.07	4.64	0.29	0.32
Basic earnings per share (in dollars per share)		0.65	5.14	0.61	0.58	0.61	0.63	0.51	0.56	6.98	2.31	2.46
Diluted:
Continuing operations (in dollars per share)		0.58	0.61	0.61	0.54	0.55	0.55	0.41	0.49	2.34	2.01	2.12
Discontinued operations (in dollars per share)		0.07	4.52	0	0.04	0.06	0.08	0.09	0.07	4.63	0.29	0.32
Diluted earnings per share (in dollars per share)		$ 0.65	$ 5.13	$ 0.61	$ 0.58	$ 0.61	$ 0.63	$ 0.50	$ 0.56	$ 6.97	$ 2.30	$ 2.44
Discontinued Operations, Held-for-Sale | Critical Care
Effect of Fourth Quarter Events [Line Items]
Income from discontinued operations, net of tax	$ 3,300.0		$ 3,300.0